tgdcc-e1a
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00102622)
Timeline
Indications
Studied for
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tgdcc-e1a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00102622 | Phase 1 | Dec 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Texas at Houston |
| NCT02157870 | Phase 2 | Dec 1, 2004 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2004 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2004 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2004 |
3 organizations
Page 1 / 1